Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combined With Anlotinib and Chemotherapy in ES-SCLC
NCT04731909Phase 2Unknown
- Sponsor
- Army Medical University
- Start
- Oct 2018
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and anlotinib in small cell lung cancer (SCLC), sponsored by Army Medical University. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
toripalimabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04731909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731909.